about
Molecular clues into the pathogenesis of statin-mediated muscle toxicity.Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake.Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.Myotonic potentials in statin-induced rhabdomyolysis.Benign prognosis in idiopathic hyper-CK-emia.Single-fiber electromyography in hyperCKemia: the value of fiber density.
P2860
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Cholesterol-lowering agent myopathy (CLAM)
@ast
Cholesterol-lowering agent myopathy (CLAM)
@en
Cholesterol-lowering agent myopathy (CLAM)
@nl
type
label
Cholesterol-lowering agent myopathy (CLAM)
@ast
Cholesterol-lowering agent myopathy (CLAM)
@en
Cholesterol-lowering agent myopathy (CLAM)
@nl
prefLabel
Cholesterol-lowering agent myopathy (CLAM)
@ast
Cholesterol-lowering agent myopathy (CLAM)
@en
Cholesterol-lowering agent myopathy (CLAM)
@nl
P2093
P356
P1433
P1476
Cholesterol-lowering agent myopathy (CLAM)
@en
P2093
P304
P356
10.1212/WNL.41.7.1159
P407
P577
1991-07-01T00:00:00Z